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Abstract
Background: Albumin-glutaraldehyde glue gained a widespread acceptance in repair of superficial lung defects
associated with alveolar air leaks (AAL). As its sealing efficacy has not yet been thoroughly corroborated by clinical
studies, we sought to assess the properties of commercially available albumin-glutaraldehyde glue (BioGlue™) in an
in vitro lung model.
Methods: The lower lobe of freshly excised swine lung (n = 10) was intubated and ventilated. A focal superficial
parenchymal defect (40 × 25 mm) was created on the inflated lung. AAL was assessed with increasing inspired tidal
volume (TVi). After glue application, AAL was assessed until burst failure occurred. To evaluate glue elasticity, the
length of defect was recorded in the inflated lung.
Results: Superficial parenchymal defects resulted in AAL increasing with ascending TVi. Multiple linear regression
analysis revealed strong correlation between AAL and maximal inspiratory pressure. There was one application
error. At TVi = 400, 500, 600, 700, 800 and 900 ml, BioGlue™ achieved complete sealing in nine, six, five, four two
and one specimens, respectively. Mean burst pressure was 38.0 ± 4.2 cmH2O. All sealant failures were cohesive.
BioGlue™ allowed an expansion of covered lung defects of 1.5 ± 1.7 mm.
Conclusions: Our in vitro tests demonstrated a high sealing efficacy of BioGlue™ for repair of superficial lung
defects. Due to the rigid nature, caution should be taken to use this kind of sealant in trapped lungs.
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Abstrakt
Hintergrund: Die Wirksamkeit von chirurgischen Klebstoffen zur Behandlung der alveolo-pleuralem Luftleck (AAL)
ist immer noch kontrovers diskutiert. Wir evaluierten in dieser Studie die Abdichtungswirksamkeit von einem
Albumin-Glutaraldehyd-Kleber BioGlue™ mittels eines in vitro Lungenmodels.
Methode: Der Unterlappen von frisch entnommenen Schweinlungen (n = 10) wurde intubiert und beatmet. Eine
pleurale Läsion (40 × 25 mm) wurde erstellt und APL mit steigendem inspiratorischem Tidalvolumen (TVi)
untersucht. Nach Applikation von BioGlue™ wurde AAL auf die gleiche Weise gemessen bis zur Auftritt von
Kleberbruch. Zur Untersuchung der Elastizität des Klebers wurde die Länge der pleuralen Läsion gemessen.
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Ergebnis: Die oberflächliche pleurale Läsion führte bei aufsteigendem TVi zum Anstieg von AAL. Multiple lineare
Regressionsanalyse ergab eine starke Korrelation zwischen AAL und dem maximalen inspiratorischen Druck.
Applikationsfehler trat bei einem Test auf. Bei TVi = 400, 500, 600, 700, 800 und 900 ml führte BioGlue™ zur
kompletten Versieglung in neun, sechs, fünf, vier, zwei und einem Test. Der mittlere Bruchdruck betrug 38.0 ± 4.2
cmH2O. Es wurde nur kohäsiver Kleberbruch gefunden. Nach der Kleberapplikation hat sich die Länge der pleuralen
Läsion um 1.5 ± 1.7 mm gedehnt.
Schlussfolgerung: Unsere in vitro Versuche zeigten eine zuverlässige Versiegelung der oberflächlichen
Lungendefekte durch BioGlue™. Aufgrund der Streifigkeit des Klebers ist Vorsicht bei der Verwendung derartigen
Klebers an gefesselter Lunge geboten.
Background
Superficial lung defect is a common intraoperative com-
plication of lung surgery, particularly following pleural de-
cortication, dissection of firm pleural adhesions and
division of incomplete fissures [1–3]. It results in alveolar
air leaks (AAL) associated with delayed removal of chest
tubes, prolonged hospital stays, increased postoperative
morbidity and patient discomfort [4, 5]. In the past decade
surgical sealants have been increasingly used in treating
AAL as adjuncts to conventional closing techniques
including suturing and stapling. The commonly used seal-
ants are human thrombin-fibrinogen sponge (TachoSil®;
Takeda Pharmaceutical Company Limited, Osaka, Japan),
albumin-glutaraldehyde glue (BioGlue™; CryoLife Europa
Ltd., Surrey, UK) and synthetic polymer sealants (Tis-
suePatch™, Tissuemed Ltd, Leeds, UK; CoSeal®, Baxter
Healthcare, Fremont, CA) [5, 6]. However, a body of
clinical trials assessing sealant efficacy yielded inconsist-
ent results, thus raising questions about evidence-based
sealant use in lung surgery [5–7]. This might be attributed
to a number of factors like small sample sizes, inherent
flaws in study design or heterogeneity of clinical charac-
teristics in study and control groups [5, 8].
Bioglue™ (CryoLife Europa Ltd., Surrey, UK) is a two-
component sealant composed of bovine serum albumin
and glutaraldehyde [9]. The aldehyde groups of glutaralde-
hyde react with the amine groups of bovine serum albumin
and those present in the extracellular matrix and cell
surface, resulting in strong cross-linking after 2–3 min.
Bioglue™ has been widely used in cardiovascular surgery
due to its high hemostatic efficacy [10–12]. In recent years
BioGlue™ gained widespread acceptance as an adjunct in
treating AAL in lung surgery [13]. So far, the pneumostatic
efficacy of BioGlue™ has not been thoroughly evaluated. In
the present study we sought to examine sealing efficacy
and elasticity of BioGlue™ for repair of superficial lung de-
fects by means of an established in vitro lung model [8].
Methods
Experimental protocol
Lungs of German Landrace pigs were freshly excised in
a local slaughterhouse. Within two hours after harvest,
the lungs were dissected along the trachea until the tra-
cheal bifurcation was reached. The lower lobe was se-
lectively intubated, ventilated and immersed in water to
ensure impermeability. After being connected to the
ventilation machine (Evita, Dräger, Lübeck, Germany),
the lower lobe was ventilated in volume-controlled mode
with a PEEP of 5 cmH2O, an I:E ratio of 1:2 and a fre-
quency of 12/min. The lower lobe was fully inflated
when inspiratory tidal volume (TVi) was ≥ 400 ml. Over-
inflation of the lobe was observed with TVi ≥ 800 ml. To
create a standardized superficial parenchymal lesion, a
rectangle measuring 40 × 25 mm was marked on the
fully inflated lower lobe with a marker pen. Using a
small, conic headed drill, a defect was created by care-
fully applying pressure to the marked site, starting at the
edges and advancing toward the middle of the desig-
nated area. Marker spots were then added to the cranial
and caudal edge of the lesion (Fig. 1). TVi was increased
in steps, recording respiratory parameters including ex-
piratory tidal volume (TVe), maximal inspiratory pres-
sure (Pmax), plateau pressure (Pplat), resistance and
compliance for each subsequent step until a Pmax of 40
cmH2O was reached. AAL was calculated as difference
between TVi and TVe.
Thereafter, BioGlue™ was applied to the lesion by care-
fully meandering along the surface, in compliance with
Fig. 1 A superficial lesion (40 × 25 mm) on lower lobe with marker
spots at cranial and caudal edge
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user guidelines, and respecting a safety margin of one
cm to all sides (Fig. 2). In the present experiment Bio-
Glue™ was applied exclusively in two mL pre-filled syrin-
ges, using only one sample for each lesion. After 60 s
full sealant adhesion was achieved and the glue hard-
ened. The lower lobe was then ventilated again with TVi
rising slowly from 100 ml. Commencing at 400 ml TVi
the same ventilation parameters as before were recorded.
AAL at the site of pleural defect were assessed by sub-
mersion tests and graded according to Macchiarini scale
as grade 0 (no leak), grade 1 (countable bubbles), grade
2 (stream of bubbles) and grade 3 (coalescent bubbles)
[14]. Sealing was considered successful, if no bubbles
were observed (Macchiarini grade 0). The distance be-
tween both marker spots was measured to evaluate seal-
ant elasticity. In case of sealant failure Pmax was
recorded as burst pressure (BP). Pmax tolerated at the
TVi, at which sealing was last achieved, was considered
maximally tolerated pressure (MTP). Burst failure was
furthermore categorized into adhesive or cohesive failure.
Adhesive failure occurred at the interface between sealant
and parenchymal defect. Cohesive failure was defined as
failure within the sealant. Application error occurred,
when cohesive or adhesive failure was observed before
starting the test at 400 ml TVi. Two independent
investigators noted all results. A third investigator would
arbitrate any disagreement.
Finally, lung specimen containing the parenchymal lesion
along with attached sealant were resected and fixed with
glutaraldehyde. The specimen were embedded in paraffin
and processed to obtain sections for haematoxylin-eosin
staining.
Statistical analysis
Normality of variables was tested using the Kolmogorov-
Smirnov one-sample-test. Descriptive statistics are
presented as mean ± standard deviation in case of normal
distribution. Multiple linear regression was used to
determine the ventilation parameters’ correlation with
AAL. Statistical significance was assumed if p < 0.05. All
statistical analysis was performed using SPSS (version 16.0
for Windows; SPSS Inc., Chicago, Illinois, USA).
Results
A total of five pilot tests were performed prior to start-
ing the experiment to ensure proper application of seal-
ant and assessment of sealing efficacy. The results of
these tests were not included in the data set or statistical
analysis. Thereafter ten consecutive tests were under-
taken. In the assessment before sealant application AAL
increased with ascending TVi. Multiple linear regression
analysis revealed strong correlation between AAL and
Pmax (p < 0.001).
We observed one application error. Following sealant
application, nine lungs were still considered airtight at
TVi of 400 ml, six at TVi of 500 ml, seven at TVi of
600 ml and four at TVi of 700 ml. Two lungs remained
sealed even at TVi of 800 ml, with one lung remaining
sealed until 1000 mL TVi. Graphic interpretation of
AAL with ascending TVi is presented in Fig. 3. Mean BP
was 38.0 ± 4.2 cmH2O and mean MTP was 36.3 ± 6.1
cmH2O. All burst failures were cohesive. BioGlue™
allowed an average length expansion of 1.5 ± 1.7 mm in
relation to length at TVi of 400 ml.
Haematoxylin-eosin staining of sealed lung specimen
showed a sealant layer attaching densely to underlying
parenchymal lesion (Fig. 4) and visceral pleura at the le-
sion edge (Fig. 5).
Fig. 2 Application of BioGlue™ to the superficial lesion of
lung parenchyma
Fig. 3 Graphic assessment of mean alveolar air leak before and after
sealant application
Bures et al. Journal of Cardiothoracic Surgery  (2016) 11:63 Page 3 of 5
Dicsussion
Superficial lesions of lung parenchyma occur regularly in
lung surgery, especially in pleural decortation, dissection
of firm pleural adhesions and division of incomplete
fissures. One of the consequences is AAL resulting in
delayed removal of chest tubes, prolonged hospital stays
as well as higher postoperative morbidity [1, 3, 15]. The
utility of surgical sealants as adjunct to conventional
sealing techniques has been progressively recognized in
lung surgery over the past decade [16, 17].
BioGlue™ is a two-component sealant consisting of bo-
vine serum albumin and glutaraldehyde, and has been
widely used for achieving haemostasis in cardiovascular
surgery. In the recent past BioGlue™ has also seen an in-
crease in use for repair of superficial lung defects. How-
ever, its true sealing efficacy remains unclear, which is at
least partly due to inconsistent results of clinical trials.
In a prospective, randomized controlled trial, Tansley
et al. examined 52 patients with post-thoracotomy AAL
and found significant differences in duration of intercos-
tal drainage for patients treated with BioGlue™ over
those in whom only surgical closing techniques were
used [18]. However, this advantage could not be con-
firmed in another multicenter prospective randomized
clinical trial, in which Allen and co-workers randomized
161 patients in a 2:1 ratio to receive topical application
of BioGlue™ or control for at least one significant AAL
following lung resection [19]. They found no significant
difference in the duration to chest tube removal.
The present in vitro experiment aimed to test the
sealing efficacy of BioGlue™ using an established lung
model, which simulated a real scenario in lung surgery [8].
The results showed a high efficacy of BioGlue™ in treating
AAL. BioGlue™ withstood very high inspiratory pressures,
as reflected by the mean BP of 38.0 cmH2O – a respira-
tory pressure higher than in routine clinical settings. This
suggests that BioGlue™ might be a useful tool for treat-
ment of AAL, particularly in patients requiring aggressive
mechanical ventilation. Albeit, the overall clinical benefits
of BioGlue™ need to be further evaluated by well-designed
prospective, randomized clinical trials. The authors are
going to launch an experiment to compare BioGlue™ with
other commonly used surgical sealants regarding sealing
efficacy by means of the present in vitro lung model.
Additionally, our experiment analysed elastic proper-
ties of BioGlue™, which seem to comprise this sealant’s
main weakness. After application of BioGlue™ only very
little elasticity remained in the affected lung tissue,
which might be of concern in patients with already
trapped lung. Beside local effects, sealant run-off during
application and ensuing restriction after glue hardening
can further augment its rigidity. It appears that strong
cross-links between albumin and glutaraldehyde, which
ensure the great durability of BioGlue™, result in marked
glue rigidity. This characteristic was previously men-
tioned by Belcher et al., where the sealant is described as
having “a rigid, inelastic nature that does not expand
with the underlying lung”, possibly increasing the risk
for inflammation [20]. A study by Azadani et al. on
mechanical properties of surgical glues revealed that
BioGlue™ had a far lower compliance than comparable
products [21]. Our tests provided quantitative data in
this regard and could contribute to a deeper understand-
ing of biomechanical properties of BioGlue™.
Concerning the bovine serum contained in Bioglue™, the
risk of blood borne diseases exists for treated patients.
Other reservations about the sealant concern toxicity of the
glutaraldehyde component, as topified by Fürst et al. in a
combined in vitro/in vivo experiment [22]. Here a cytotoxic
effect of glutaraldehyde was found in vitro for human and
mouse growth cells and an inflammation of the liver and
aorta in vivo, suggesting BioGlue™ be used with caution.
Fig. 4 BioGlue™ glue (a) attached densely the underlying lung
parenchymal lesion (b)
Fig. 5 BioGlue™ glue (a) adhesive to the visceral pleura (arrow) with
underlying parenchyma (b)
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Possible limitations of this in vitro trial include a cer-
tain inevitable variation in parenchymal lesion size. We
minimized these potential confounders by using lungs
from pigs of equal weight (around 80 kg) and size and
by inducing standardized lesions. As all lower lobes were
fully inflated with a TVi of 400 ml, no differences were
noted in this regard. Judgment of sealing and measure-
ment of lesion length might be prone to information
bias. To counteract this, measurements were undertaken
by two independent investigators and arbitrated by a
third, if necessary. In the end our in vitro tests deliver
quantitative results that may contribute to further un-
derstanding and use of BioGlue™ as adjunct therapy for
AAL.
Conclusions
Our in vitro tests suggest that BioGlue™ might be a useful
adjunct in treating AAL, especially in patients requiring
high ventilation pressures. Caution should be advised for
the utility of this sealant in patients with trapped lung due
to its rigidity.
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